Advances in cervical cancer pharmacotherapies

Is the progression free survival advantage of concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin in patients with advanced cervical cancer worth the additional cost? A cost-effectiveness analysis

(2013) B. Smith et al.   GYNECOLOGIC ONCOLOGY

Immunogenicity of 2 Doses of HPV Vaccine in Younger Adolescents vs 3 Doses in Young Women

(2013) Simon R. M. Dobson et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Patient Income Level and Cancer Clinical Trial Participation

(2013) Joseph M. Unger et al.   JOURNAL OF CLINICAL ONCOLOGY

Cost effectiveness of concurrent gemcitabine and cisplatin with radiation followed by adjuvant gemcitabine and cisplatin in patients with stages IIB to IVA carcinoma of the cervix

(2012) Neil T. Phippen et al.   GYNECOLOGIC ONCOLOGY

A Gynecologic Oncology Group phase III randomized trial of weekly cisplatin and radiation versus cisplatin and tirapazamine and radiation in stage IB2, IIA, IIIB and IVA cervical carcinoma limited to the pelvis

(2012) P. DiSilvestro et al.   GYNECOLOGIC ONCOLOGY

INCA-GYN001: Erlotinib added to cisplatin and definitive radiotherapy in untreated patients with locally advanced squamous cell cervical carcinoma — A phase II trial and correlative tumor molecular profiling

(2012) A. Rodrigues et al.   GYNECOLOGIC ONCOLOGY

A phase I trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: A gynecologic oncology group study

(2012) Kathleen N. Moore et al.   GYNECOLOGIC ONCOLOGY

Chemotherapy for advanced and recurrent cervical carcinoma: Results from cooperative group trials

(2012) Charles A. Leath et al.   GYNECOLOGIC ONCOLOGY

A Phase II Study of Bevacizumab in Combination With Definitive Radiotherapy and Cisplatin Chemotherapy in Untreated Patients With Locally Advanced Cervical Carcinoma: Preliminary Results of RTOG 0417

(2012) Tracey E. Schefter et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Tissue Platinum Concentration and Tumor Response in Non–Small-Cell Lung Cancer

(2012) Eric S. Kim et al.   JOURNAL OF CLINICAL ONCOLOGY

Achieving the Best of Both Worlds

(2012) Andrew H. Ko et al.   JOURNAL OF CLINICAL ONCOLOGY

Are We Making Progress in Curing Advanced Cervical Cancer?

(2011) Gillian Thomas   JOURNAL OF CLINICAL ONCOLOGY

Survival Data From a Phase II, Open-Label Study of Pazopanib or Lapatinib Monotherapy in Patients With Advanced and Recurrent Cervical Cancer

(2011) Bradley J. Monk et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III, Open-Label, Randomized Study Comparing Concurrent Gemcitabine Plus Cisplatin and Radiation Followed by Adjuvant Gemcitabine and Cisplatin Versus Concurrent Cisplatin and Radiation in Patients With Stage IIB to IVA Carcinoma of the Cervix

(2011) Alfonso Dueñas-González et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II, Open-Label Study of Pazopanib or Lapatinib Monotherapy Compared With Pazopanib Plus Lapatinib Combination Therapy in Patients With Advanced and Recurrent Cervical Cancer

(2010) Bradley J. Monk et al.   JOURNAL OF CLINICAL ONCOLOGY

Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer

(2010) Jennifer S. Temel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: A Gynecologic Oncology Group Study

(2009) David H. Moore et al.   GYNECOLOGIC ONCOLOGY

Phase III Trial of Four Cisplatin-Containing Doublet Combinations in Stage IVB, Recurrent, or Persistent Cervical Carcinoma: A Gynecologic Oncology Group Study

(2009) Bradley J. Monk et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Bevacizumab in the Treatment of Persistent or Recurrent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study

(2009) Bradley J. Monk et al.   JOURNAL OF CLINICAL ONCOLOGY

Reducing Uncertainties About the Effects of Chemoradiotherapy for Cervical Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data From 18 Randomized Trials

(2008)   JOURNAL OF CLINICAL ONCOLOGY